SmithRx is a disruptive force in the pharmacy benefits management industry. Founded in 2016, the startup's mission is clear - to reduce the cost and complexity of pharmacy benefits for America's employers and patients. The company's transparent, pass-through model, independent of insurance companies and pharmacies, ensures that its incentives are 100% aligned with its customers. This commitment to transparency and customer-centricity has attracted a $60.00M Series C investment from Venrock on 23 January 2024. SmithRx's innovative approach, underpinned by modern technology and cost-saving programs, aligns with current industry pain points, positioning it as a formidable contender in the Health Care, Information Technology, and Pharmaceutical industries. In a market dominated by overly complex monopolies, SmithRx stands out as a beacon of integrity and efficiency, offering hope for a more streamlined and cost-effective future in pharmacy benefits management.
Funding Stage | Amount | No. Investors | Investors | Date |
---|---|---|---|---|
Series C | $60.00M | 1 | 23 Jan 2024 | |
Series B | $27.16M | 4 | Zachary Hargreaves | 10 Mar 2022 |
Series A | Unknown | 1 | Konstantin von Unger | 03 Jan 2021 |
Series A | Unknown | 1 | 01 Dec 2019 | |
Series A | $5.50M | 6 | 31 Jul 2018 |
No recent news or press coverage available for SmithRx.